Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2003;108:1724-1728
Published online before print September 15, 2003, doi: 10.1161/01.CIR.0000087604.27270.5B
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
108/14/1724    most recent
01.CIR.0000087604.27270.5Bv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yamani, M. H.
Right arrow Articles by Young, J. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yamani, M. H.
Right arrow Articles by Young, J. B.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Heart Transplantation
*Organ Donation
Related Collections
Right arrow Coronary imaging: angiography/ultrasound/Doppler/CC
Right arrow CV surgery: transplantation, ventricular assistance, cardiomyopathy
Right arrow Acute Cerebral Hemorrhage

(Circulation. 2003;108:1724.)
© 2003 American Heart Association, Inc.


Clinical Investigations

Donor Spontaneous Intracerebral Hemorrhage Is Associated With Systemic Activation of Matrix Metalloproteinase-2 and Matrix Metalloproteinase-9 and Subsequent Development of Coronary Vasculopathy in the Heart Transplant Recipient

Mohamad H. Yamani, MD; Randall C. Starling, MD, MPH; Daniel J. Cook, PhD; E. Murat Tuzcu, MD; Ashraf Abdo, MD; Philip Paul, PhD; Kimerly Powell, PhD; Norman B. Ratliff, MD; Yang Yu; Patrick M. McCarthy, MD; James B. Young, MD

From the Departments of Cardiovascular Medicine (M.H.Y., R.C.S., E.M.T., Y.Y., J.B.Y.), Allogen Laboratory (D.J.C., A.A., P.P.), Biomedical Engineering (K.P.), Anatomic Pathology (N.B.R.), and Cardiothoracic Surgery (P.M.M.), Kaufman Center for Heart Failure, The Cleveland Clinic Foundation, Cleveland, Ohio.

Correspondence to Mohamad H. Yamani MD, Cleveland Clinic Foundation, Cardiovascular Medicine, F25, 9500 Euclid Ave, Cleveland, OH 44195. E-mail Yamanim{at}ccf.org

Received May 12, 2003; revision received June 30, 2003; accepted July 2, 2003.

Abstract

Background— Matrix metalloproteinase (MMP)-2 and MMP-9 have been shown to play a role in the progression of hemorrhagic stroke. We hypothesized that donor intracerebral hemorrhage (ICH) is associated with activation of the metalloproteinases before transplantation that play a key role in the subsequent development of transplant vasculopathy.

Methods and Results— We evaluated mRNA expressions of MMP-2 and MMP-9 in donor spleen lymphocytes (before transplantation) and in heart biopsies at 1 week after transplantation in 20 recipients from ICH donors and 20 recipients from trauma donors. Patients underwent serial coronary intravascular ultrasound, and interstitial myocardial fibrosis was quantified at 1 year. The baseline characteristics were similar except for increased donor age in the ICH group. Heart biopsies from the ICH group showed significant increased expression of MMP-2 (17-fold, P<0.0001) and MMP-9 (20-fold, P<0.0001) compared with the trauma group. Furthermore, the ICH group showed 1.8-fold (P=0.016) increased mRNA expression of MMP-2 and 1.7-fold (P=0.015) increased mRNA expression of MMP-9 in the donor spleen lymphocytes, suggesting the presence of systemic activation of metalloproteinases before transplantation. At 1 year, the ICH group showed increased myocardial fibrosis and accelerated coronary vasculopathy. Using multivariate regression analysis, MMP-9 was found to be associated with increased risk for vasculopathy independent of donor age (OR, 2.41; P=0.01; 95% CI, 1.24 to 4.69).

Conclusions— This is the first report to describe systemic activation of MMP-2 and MMP-9 in donors with intracerebral hemorrhage and subsequent development of allograft vasculopathy.


Key Words: metalloproteinases • hemorrhage • transplantation




This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
K. Shimizu and R. N. Mitchell
The Role of Chemokines in Transplant Graft Arterial Disease
Arterioscler Thromb Vasc Biol, November 1, 2008; 28(11): 1937 - 1949.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. R. Mehra, P. A. Uber, D. Walther, M. Vesely, J. G. Wohlgemuth, J. Prentice, D. Tayama, and M. Billingham
Gene Expression Profiles and B-Type Natriuretic Peptide Elevation in Heart Transplantation: More Than a Hemodynamic Marker
Circulation, July 4, 2006; 114(1_suppl): I-21 - I-26.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. H. Yamani, N. B. Ratliff, D. J. Cook, E. M. Tuzcu, Y. Yu, R. Hobbs, G. Rincon, C. Bott-Silverman, J. B. Young, N. Smedira, et al.
Peritransplant Ischemic Injury Is Associated With Up-Regulation of Stromal Cell-Derived Factor-1
J. Am. Coll. Cardiol., September 20, 2005; 46(6): 1029 - 1035.
[Abstract] [Full Text] [PDF]